SCHEMBL23608969

SCHEMBL23608969

FC1(F)CCC(CNc2ccc(NCCn3cncn3)cn2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
KMT2A Q03164 1/20 0.40
PIM1 P11309 1/20 0.39
IRAK1 P51617 1/20 0.36
FPR3 P25089 2/20 0.36
FPR2 P25090 2/20 0.36
VNN1 O95497 1/20 0.35
KDM5A P29375 1/20 0.34
KDM5B Q9UGL1 1/20 0.34
CTSS P25774 1/20 0.33
CTSK P43235 1/20 0.33
CRHR1 P34998 2/20 0.33
AOC3 Q16853 1/20 0.33
MAPK1 P28482 1/20 0.32
HTT P42858 1/20 0.32
CYP19A1 P11511 1/20 0.32
NPY5R Q15761 3/20 0.32
P2RX7 Q99572 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23608962 0.84 IRAK1 (0.39) SMN1; SMN2ALDH1A1HPGDKMT2APIM1
SCHEMBL23608970 0.75 CYP19A1 (0.46) SMN1; SMN2ALDH1A1HPGDKMT2AMAPK1
SCHEMBL30406442 0.75 CYP19A1 (0.46) SMN1; SMN2ALDH1A1HPGDKMT2AMAPK1
SCHEMBL23608948 0.74 GPR55 (0.47) SMN1; SMN2ALDH1A1HPGDKMT2APIM1
SCHEMBL23608960 0.72 IRAK1 (0.33) IRAK1NPY5R
SCHEMBL23609126 0.71 CYP19A1 (0.40) SMN1; SMN2ALDH1A1HPGDKMT2AFPR3
SCHEMBL23609365 0.70 PIM1 (0.42) PIM1IRAK1KDM5AKDM5BCTSS
SCHEMBL23609608 0.70 PIM1 (0.42) SMN1; SMN2ALDH1A1HPGDKMT2APIM1
SCHEMBL27304051 0.69 EGLN2 (0.43) PIM1CTSSCTSK
SCHEMBL23608968 0.69 CYP19A1 (0.39) SMN1; SMN2ALDH1A1HPGDKMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230117592-A1 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2023-04-20 US disclosed
WO-2021133689-A2 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230117592-A1 LIPOXYGENASE INHIBITORS ALOX15B, ALOX12, ALOX5 SMN1; SMN2 243/4885ALDH1A1 203/4885HPGD 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.